U.S. Allows Continued Sale Of Abbott Weight-Loss Drug
Article Abstract:
The Food and Drug Administration ruled that Abbott Laboratories can continue to sell its weight-loss drug Meridia, but asked that the company remind doctors that people with cardiovascular problems should abstain from taking the drug.
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
$60 Million Deal In Pfizer Suit
Article Abstract:
Pfizer Inc. has settled a class-action lawsuit over the life threatening side effects of the diabetes drug Rezulin. The drug has now been withdrawn from the market.
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
New York's Pension Fund Files Own Suit Against Merck
Article Abstract:
New York's main pension fund has sued Merck and Co. for misleading shareholders about the safety of the discontinued pain medication Vioxx.
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: U.S. Insurer Of Pensions Says Its Deficit Has Soared. U.S. Cancels Pension Plan At Kaiser. Pension Gap Is Closing, G.M. Reports
- Abstracts: Eyetech Pins Its Hopes (And Shares) On New Drug. Medical Editors Likely To Call for Registration Of Drug Tests at Outset
- Abstracts: Unmasking That Pension Consultant. U.S. Regulator Threatens Action Against A.I.G. On Press Releases. Funds Manager Is Said to Face S.E.C. Inquiry
- Abstracts: Weakness in Demand Shrivels Japan's Output. Despite a Jolt, Japan's Mood Remains Upbeat. India Sets A Fast Pace, Expanding 8.2% in Year
- Abstracts: Witness Says Ebbers Urged Manipulations At WorldCom. Bernard Ebbers: Victim Himself Or Mastermind? S.E.C. Wants to Know How Telecoms Count Customers